Dechra Pharmaceuticals PLC — Board/Management Information 2016

Nov 9, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7795O

Dechra Pharmaceuticals PLC

09 November 2016

9 November 2016

Dechra® Pharmaceuticals PLC

(Dechra, Company or the Group)

Board Appointment

Appointment of Non-Executive Director

Dechra is pleased to announce that Lawson Macartney has been appointed to the Board as Non-Executive Director with effect from 1 December 2016. 

Dr Macartney, a qualified veterinarian, is Chairman of Viking Therapeutics Inc., a developer of novel therapeutics for patients suffering from metabolic and endocrine disorders, and an adviser to several biopharmaceutical companies and life science consultancies.  Prior to this, Dr Macartney was President and CEO of Ambrx Inc., Senior Vice President and Head of Emerging Business at Shire AG, and held various senior, global commercial, sales, marketing and strategy roles at GlaxoSmithKline plc.

Ian Page, Chief Executive Officer, Dechra Pharmaceuticals said:

"We are delighted to welcome Lawson to the Board and we look forward to working with him.  Lawson's 30 years of experience gained in the global pharmaceutical industry will bring further knowledge and expertise of product development to the Board."

There are no other disclosures to be made in respect of Lawson Macartney, pursuant to Listing Rule 9.6.13R.

Enquiries to:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer
Office:  +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523 e-mail: fiona@tooleystreet.com

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and relates products business.  Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 

For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAFSDFLUFMSEIF